Karen Drexler Net Worth

The estimated Net Worth of Karen Drexler is at least $2.68 Milhão dollars as of 29 April 2024. Ms. Drexler owns over 425 units of Resmed stock worth over $2,136,162 and over the last 6 years she sold RMD stock worth over $225,930. In addition, she makes $314,946 as Independent Director at Resmed.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Drexler RMD stock SEC Form 4 insiders trading

Karen has made over 2 trades of the Resmed stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 425 units of RMD stock worth $91,341 on 29 April 2024.

The largest trade she's ever made was selling 594 units of Resmed stock on 2 February 2023 worth over $134,589. On average, Karen trades about 78 units every 35 days since 2018. As of 29 April 2024 she still owns at least 8,446 units of Resmed stock.

You can see the complete history of Ms. Drexler stock trades at the bottom of the page.

Karen Drexler biography

Karen Drexler serves as Independent Director of the Company. Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices and diagnostics. she was the CEO and a board member of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for point-of-care medical testing. Ms. Drexler also serves on the boards of Tivic Health, a bioelectric medicine company initially focused on relief of sinus pain and pressure, VIDA Health, the leading company in Al-powered lung intelligence solutions and analytics, and Microbide USA, which is commercializing stable aldehyde-based biocides that eradicate germs and pathogens. she served as chair of the board of Hygieia, Inc., a digital insulin therapy company, and remains involved as an advisor to the CEO. She also acts as a senior strategic advisor for other early-stage companies and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Ms. Drexler has served on numerous private company boards in the fields of diagnostics, medical devices, and digital health. She is an active mentor and advisor with Astia, a global nonprofit that supports high-potential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders, and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women’s Health Councils for Springboard, an accelerator for women-led technology-oriented companies. Through her work with Astia, Springboard, and StartX, she interacts with many promising young medtech companies. Ms. Drexler was founder, president, and CEO of Amira Medical Inc., a private company focused on minimally invasive glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. Before Amira Medical, she held management roles at LifeScan and played a key role in its

What is the salary of Karen Drexler?

As the Independent Director of Resmed, the total compensation of Karen Drexler at Resmed is $314,946. There are 19 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.

How old is Karen Drexler?

Karen Drexler is 60, she's been the Independent Director of Resmed since 2017. There are 9 older and 12 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.

Insiders trading at Resmed

Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, eDavid Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.

What does Resmed do?

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Complete history of Ms. Drexler stock trades at Resmed e Outset Medical

Resmed executives and stock owners

Resmed executives and other stock owners filed with the SEC include:

• Michael Farrell,
  Chief Executive Officer, Director
• Robert Douglas,
  President, Chief Operating Officer
• Jim Hollingshead,
  President – sleep and respiratory care business
• Rajwant Sodhi,
  President – Software as a Service Business (SaaS)
• Brett Sandercock,
  Chief Financial Officer
• Michael J. Farrell BE, SM, MBA,
  CEO & Director
• David Pendarvis,
  Chief Administrative Officer, Global General Counsel, Secretary
• Michael J. Farrell BE, MBA, SM,
  CEO & Director
• Robert A. Douglas,
  Pres & COO
• Dr. James R. Hollingshead Ph.D.,
  Pres of Sleep & Respiratory Care Bus.
• Brett A. Sandercock,
  Chief Financial Officer
• Peter Farrell,
  Non-Executive Chairman of the Board
• Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD,
  Founder & Non-Exec. Chairman
• Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM,
  Founder & Non-Exec. Chairman
• Ronald Taylor,
  Lead Independent Director
• Carol Burt,
  Independent Director
• Richard Sulpizio,
  Independent Director
• Harjit Gill,
  Independent Director
• Jan De Witte,
  Independent Director
• Karen Drexler,
  Independent Director
• Justin Leong,
  President – Asia and Latin America
• Urvashi Tyagi,
  Chief Technology Officer
• Nupur Bhushan,
  Chief People Officer
• David B. Pendarvis,
  Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
• Amy Wakeham,
  VP of Investor Relations & Corp. Communications
• Constance C. Bienfait,
  Director of Investor Relations
• Kaushik Ghoshal,
  Pres of SaaS Bus. & CTO
• John P Wareham,
  Director
• Christopher G Roberts,
  Director
• Donald Darkin,
  Sr. Vice President, Pat Inter
• Gary W Pace,
  Director
• Anne Reiser,
  President - ResMed Europe
• Richard Mc Hale,
  President, RC Business
• Inc Resmed,
  Director
• James Hollingshead,
  President, Sleep Business
• Kieran Gallahue,
  President, Global
• Paul Eisen,
  Vice President, Europe & Asia
• Donagh Mccarthy,
  Director
• Adrian M Smith,
  CFO
• Klaus H Shindhelm,
  Sr. Vice President, Operations
• Keith Serzen,
  Chief Operating Officer
• Louis A Simpson,
  Director
• Christopher Bartlett,
  Director
• Walter Flicker,
  VP and Asst. Corp. Secretary
• Lasse Beijer,
  COO-Europe
• Stein Jacobsen,
  COO, Europe
• Michael A Quinn,
  Director
• Kaushik Ghoshal,
  President, SaaS Business
• Lucile Blaise,
  President, Sleep & RC Business
• John Hernandez,
  Director
• Desney Tan,
  Director
• Michael J Rider,
  Global General Counsel
• Christopher Del Orefice,
  Director